Paul C Grint's Net Worth
$2.43 Million
Who is Paul C Grint?
Paul C Grint has an estimated net worth of $2.43 Million. This is based on reported shares across multiple companies, which include ILLUMINA INC, AmpliPhi Biosciences Corp, Regulus Therapeutics Inc., and Inhibikase Therapeutics, Inc..
SEC CIK
Paul C Grint's CIK is 0001236548
Past Insider Trading and Trends
2010 was Paul C Grint's most active year for acquiring shares with 6 total transactions. Paul C Grint's most active month to acquire stocks was the month of April. 2010 was Paul C Grint's most active year for disposing of shares, totalling 8 transactions. Paul C Grint's most active month to dispose stocks was the month of September. 2010 saw Paul C Grint paying a total of $130,650.00 for 45,300 shares, this is the most they've acquired in one year. In 2010 Paul C Grint cashed out on 60,800 shares for a total of $1,496,373.94, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
ILLUMINA INC (ILMN) Snapshot price: $125
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +3.66% | 295 |
—
|
—
| 8.37K |
Jan 3
| |||
Form 4
| +4.44% | 343 |
—
|
—
| 8.07K |
Oct 1
| |||
Form 4
| +4.50% | 333 |
$44.95 | $14,968.35 | 7.73K |
Jul 3
| |||
Form 4
| +24.19% | 1.44K |
—
|
—
| 7.39K |
Apr 18
| |||
Form 4
| +5.57% | 314 |
—
|
—
| 5.95K |
Apr 5
| |||
Form 4
| +34.29% | 1.44K |
—
|
—
| 5.64K |
May 10
| |||
Form 4
|
—
|
0
|
$30.09 | -$514,543.94 | 4.2K |
Scheduled
|
Oct 27
| ||
Form 4
|
—
|
0
|
$25.68 | -$426,488.00 | 4.2K |
Scheduled
|
Aug 6
| ||
Form 4
|
—
|
0
|
$23.92 | -$391,180.00 | 4.2K |
Scheduled
|
Jul 30
| ||
Form 4
| +31.25% | 1K |
$41.89 | -$33,512.00 | 4.2K |
May 10 - May 12
| |||
Form 4
| +60.00% | 1.2K |
$36.43 | -$29,144.00 | 3.2K |
May 7 - May 8
| |||
Form 4
|
∞
| 1K |
—
|
—
| 1K |
May 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 12
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
AmpliPhi Biosciences Corp (ARMP) Snapshot price: $2.33
Chief Executive Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 599 |
$0.62 | $371.38 | 599 |
Dec 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 5
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Regulus Therapeutics Inc. (RGLS) Snapshot price: $1.48
President & CEO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 25
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 16
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Inhibikase Therapeutics, Inc. (IKT) Snapshot price: $1.35
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 24
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 25
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 22
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||